Page last updated: 2024-12-05

4-nitrobenzylthioinosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-nitrobenzylthioinosine: inhibitor of nucleoside transport; acts on ENT1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65407
CHEMBL ID418509
CHEBI ID138859
SCHEMBL ID1321676
MeSH IDM0042132

Synonyms (58)

Synonym
MLS002153144
smr001230641
nitrobenzylthioinosine
nbmpr
9h-purine, 6-[[(4-nitrophenyl)methyl]thio]-9-beta-d-ribofuranosyl-
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]tetrahydrofuran-3,4-diol
s-(4-nitrobenzyl)-6-thioinosine, >=98%, solid
6-((4-nitrobenzyl)thio)-9-beta-d-ribofuranosylpurine
4-nitrobenzylthioinosine
einecs 253-753-4
6-(((4-nitrophenyl)methyl)thio)-9-beta-d-ribofuranosyl-9h-purine
nsc 296962
9h-purine, 6-(((4-nitrophenyl)methyl)thio)-9-beta-d-ribofuranosyl-
brn 1191080
6-(p-nitrobenzylthio)inosine
38048-32-7
nsc-296962
NCGC00162270-01
nbti
bdbm23617
s-(4-nitrobenzyl)-6-thioinosine
chembl418509 ,
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-{[(4-nitrophenyl)methyl]sulfanyl}-9h-purin-9-yl)oxolane-3,4-diol
4-nitrobenzylmercaptopurine ribonucleoside
6-[(4-nitrobenzyl)sulfanyl]-9-(beta-d-ribofuranosyl)-9h-purine
CHEBI:138859
NCGC00162270-02
s6-nitrobenzyl mercaptopurine riboside
s6-(4-nitrobenzyl)mercaptopurine riboside
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]oxolane-3,4-diol
6-s-[(4-nitrophenyl)methyl]-6-thioinosine
C20439
SCHEMBL1321676
A823993
6-[(4-nitrobenzyl)thio]-9-beta-d-ribofuranosylpurine
HMS2234I17
unii-gv1l2dzm2z
gv1l2dzm2z ,
s-(4-nitrobenzyl)-6-thioinosine (nbti, nbmpr)
AKOS015912710
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-((4-nitrobenzyl)thio)-9h-purin-9-yl)tetrahydrofuran-3,4-diol ,
mfcd00005745
DTXSID2040947
DYCJFJRCWPVDHY-LSCFUAHRSA-N
AS-74652
CS-W011652
6-((4-nitrobenzyl)thio)-9-.beta.-d-ribofuranosylpurine
6-((4-nitrobenzyl)thio)inosine
inosine, 6-s-((4-nitrophenyl)methyl)-6-thio-
s-(p-nitrobenzyl)-6-mercapto-9-.beta.-d-ribofuranosylpurine
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-(4-nitrobenzylthio)-9h-purin-9-yl)tetrahydrofuran-3,4-diol
NBM ,
6-{[(4-nitrophenyl)methyl]sulfanyl}-9-beta-d-ribofuranosyl-9h-purine
NCGC00162270-05
s-4-nitrophenylmethyl-6-thioinosine
s-(4-nitrobenzyl)-6-thioinosine (nbmpr)
HY-W010936
Z2091980692

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Tubercidin, an adenosine analogue, is toxic to human neuroblastoma cell lines, to peripheral blood mononuclear cells (PBMCs), and to myeloid colony-forming cells (CFU-C) as tested by a short-term labeled precursor uptake and by a clonogenic assay."( Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells.
Barankiewicz, J; Cohen, A; Estrov, Z; Freedman, MH; Kaplinsky, C; Pawlin, G; Yeger, H, 1986
)
0.27
" Doses of up to 100 microM had no significant toxic effect on uninfected host cells."( Metabolism and selective toxicity of 6-nitrobenzylthioinosine in Toxoplasma gondii.
Al Safarjalani, ON; el Kouni, MH; Guarcello, V; Naguib, FN, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The modulation of transporters during differentiation could potentially regulate drug bioavailability and cytotoxicity and should be evaluated prior to combining differentiating agents with traditional nucleoside analogs in the treatment of APL."( Nucleoside transporter expression and activity is regulated during granulocytic differentiation of NB4 cells in response to all-trans-retinoic acid.
Flanagan, SA; Meckling, KA, 2007
)
0.34
" ENTs are therefore important contributors to drug bioavailability and efficacy."( Characterization of mammalian equilibrative nucleoside transporters (ENTs) by mass spectrometry.
Abdulla, P; Chalsev, M; Chaudary, N; Coe, IR; DeSouza, L; Naydenova, Z; Reyes, G; Rose, JB; Siu, KW; Villani, A, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve for the inhibition of uridine transport by nitrobenzylthioinosine (NBMPR) was biphasic: approx."( Nucleoside transport in rat cerebral-cortical synaptosomes. Evidence for two types of nucleoside transporters.
Jarvis, SM; Lee, CW, 1988
)
0.27
" NBMPR and its 5'-monophosphate (NBMPR-P) also protected mice against potentially lethal dosage of these agents."( Treatment of mouse neoplasms with high doses of tubercidin.
Jakobs, ES; Lynch, TP; Paran, JH; Paterson, AR, 1981
)
0.26
" Dose-response curve for the inhibition of equilibrative uridine transport by N-ethylmaleimide (NEM), a sulfhydryl reagent, in these cells was biphasic."( Sensitivity to inhibition by N-ethylmaleimide: a property of nitrobenzylthioinosine-sensitive equilibrative nucleoside transporter of murine myeloma cells.
Goh, LB; Lee, CW; Tu, Y, 1995
)
0.29
"The dose-response curves for the inhibition of equilibrative uridine transport by dilazep, dipyridamole and nitrobenzylthioinosine (NBMPR) in undifferentiated HL-60 cells were biphasic."( Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C.
Lee, CW, 1994
)
0.29
" The concentration of ETV in the liver was not obviously altered during pregnancy, which indicates that dosage adjustment in pregnancy is not necessary."( Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy.
Bai, M; Jiang, H; Jiang, T; Lin, N; Lu, S; Ma, Z; Sun, D; Zeng, S; Zhou, H, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.98110.044717.8581100.0000AID485294
thioredoxin reductaseRattus norvegicus (Norway rat)Potency33.58750.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency0.02060.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency14.67770.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720579
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
gemininHomo sapiens (human)Potency7.30780.004611.374133.4983AID624296
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency17.05640.060110.745337.9330AID485367; AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)75.00000.20005.677410.0000AID678791
Equilibrative nucleoside transporter 1Homo sapiens (human)IC50 (µMol)0.00430.00013.688363.0000AID1745859; AID1912447; AID255288; AID296876; AID330912
Equilibrative nucleoside transporter 1Homo sapiens (human)Ki0.00060.00040.10381.1000AID146819; AID1798344; AID219062; AID296876; AID309988; AID330913; AID370699; AID392456
Solute carrier family 28 member 3Homo sapiens (human)Ki88.05002.10002.75003.4000AID370698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine kinaseToxoplasma gondiiKm1.10001.10001.96672.4000AID33981
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
neurotransmitter uptakeEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase-containing compound metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
neurotransmitter transportEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
lactationEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
inosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
hypoxanthine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
thymine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
excitatory postsynaptic potentialEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to glucose stimulusEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to hypoxiaEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine-containing compound transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
transport across blood-brain barrierEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 28 member 3Homo sapiens (human)
xenobiotic transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleobase transportSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
sodium ion transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine-containing compound transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleobase transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleoside transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
neurotransmitter transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleobase transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
protein bindingSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
purine-specific nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
basolateral plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
apical plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
presynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
postsynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
endoplasmic reticulum membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
brush border membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID296876Inhibition of ENT1 in human K562 cells by flow cytometric assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.
AID1660979Inhibition of Escherichia coli shiga toxin2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Structure-Activity Relationship Studies of Retro-1 Analogues against Shiga Toxin.
AID330912Binding affinity to ENT1 transporter2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.
AID370698Binding affinity to human recombinant CNT3 expressed in pig PK15NTD cells assessed as [3H]uridine uptake by beta-scintillation counter2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.
AID678791TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells2003Molecular pharmacology, May, Volume: 63, Issue:5
Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.
AID330913Displacement of 5-(SAENTA)-X8-fluorescein from human ENT1 transporter in human K562 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.
AID255288Percent inhibition against ADO transporter at 1 uM nonselective2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID370699Binding affinity to human ENT1 assessed as [3H]uridine uptake by flow cytometry2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID309988Displacement of SAENTA-fluorescein from human ENT1 in K562 cells after 45 mins by flow cytometry2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors.
AID392456Inhibition of human ENT12009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1).
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID146819Binding affinity of compound towards Nucleoside transporter es-type by facile competitive binding flow cytometric assay using the human K562 chronic melogenous leukemia cell line2003Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5
Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter.
AID33981Binding affinity at Toxoplasma gondii adenosine kinase.2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.
AID1912447Inhibition of the equilibrative nucleoside transporter (ENT1, SLC29A1) as assessed by GPCR-mediated changes in cell morphology using the impedance-based transporter activity through receptor activation (TRACT) assay (PubChem AID: 1745861)2019Scientific reports, 09-24, Volume: 9, Issue:1
Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID433257Inhibition of ENT1-mediated 99mTc-HAra-C uptake in human MIAPaCa-2 cells2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis of radiolabeled cytarabine conjugates.
AID219062Displacement of 5-(SAENTA)-X8-fluorescein from K562 cell nucleoside transporter2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors.
AID296875Inhibition of ENT1 in human K562 cells at 10 uM by flow cytometric assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.
AID1578773Antimalarial activity against multi drug-resistant Plasmodium falciparum K1 assessed as reduction in parasite growth [3H]Hypoxanthine incorporation assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID433256Inhibition of ENT1-mediated 99mTc-HAra-C uptake in human H441 cells2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis of radiolabeled cytarabine conjugates.
AID433258Inhibition of ENT1-mediated 99mTc-HAra-C uptake in human PANC-1 cells2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis of radiolabeled cytarabine conjugates.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1798344Flow Cytometric Assay from Article 10.1021/jm070311l: \\Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.\\2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (653)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990199 (30.47)18.7374
1990's243 (37.21)18.2507
2000's140 (21.44)29.6817
2010's56 (8.58)24.3611
2020's15 (2.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.30%)5.53%
Reviews10 (1.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other654 (98.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]